Cocaine

Cocaine
NEUROtiker · Public domain · source
Name	Cocaine
Caption	Structural formula and leaves of Erythroxylum coca
Legal US	Schedule II
Legal UK	Class A
Legal CA	Schedule I
Routes of administration	Intranasal; intravenous; smoked; oral
Bioavailability	Variable
Metabolism	Hepatic (esterases, CYP450)
Onset	Minutes
Duration	Short-acting
Elimination half-life	~0.5–1.5 hours
CAS number	50-36-2
ATC prefix	None

Cocaine is a tropane alkaloid derived from the leaves of the Erythroxylum coca plant that acts as a potent central nervous system stimulant and local anesthetic. It has a complex history involving Spanish Empire colonization, 19th-century pharmaceutical research, and 20th–21st-century global trade and interdiction efforts. Cocaine's biochemical actions, public health consequences, and legal responses intersect with many institutions and historical events across the Americas, Europe, and Asia.

Chemistry and Pharmacology

Cocaine is chemically classified as benzoylmethylecgonine, a tropane alkaloid synthesized in planta and characterized in the laboratory techniques of Justus von Liebig-era organic chemistry and later analytic methods such as nuclear magnetic resonance, mass spectrometry, and X-ray crystallography. Its pharmacology involves blockade of monoamine reuptake transporters—particularly the dopamine transporter—mechanisms elucidated in research environments like National Institutes of Health laboratories, and discussed in reviews from institutions such as Johns Hopkins University and Harvard Medical School. Cocaine produces sympathomimetic effects via enhanced synaptic monoamines, engaging neuroanatomic sites studied in work from University of Oxford, Columbia University, and University of California, San Francisco. Metabolism occurs hepatically via esterases and cytochrome P450 isoforms, yielding metabolites such as benzoylecgonine, findings reproduced in clinical pharmacology units at Mayo Clinic and Cleveland Clinic.

History and Cultural Context

Indigenous use of Erythroxylum coca leaves in the Andean region dates to pre-Columbian societies documented by chroniclers of the Inca Empire and later encountered by explorers tied to the Spanish Empire. Scientific isolation and commercialisation in the 19th century involved chemists connected to networks that included figures like Albert Niemann and pharmaceutical houses in Basel and Vienna. The alkaloid entered Western medicine and culture via 19th-century texts and patents, intersecting with practitioners linked to Sigmund Freud and manufacturers that evolved into corporations such as Merck Group and Bayer AG. Prohibitionist and regulatory responses emerged alongside 20th-century international diplomacy at forums like the League of Nations and later the United Nations conventions, and enforcement has involved agencies such as the Drug Enforcement Administration and the Royal Canadian Mounted Police amid cultural portrayals in works like Scarface (1983 film), reporting by outlets including The New York Times and BBC News, and political debates in jurisdictions from Colombia to Portugal.

Medical Uses and Therapeutic Research

Historically used as a topical anesthetic in ophthalmology and otolaryngology, cocaine's local anesthetic properties were characterized in surgical literature from hospitals such as Guy's Hospital and St Thomas' Hospital. Contemporary therapeutic research explores derivatives and analogs in pain management and mood disorders within clinical trials at centers like National Institutes of Health and university hospitals including Massachusetts General Hospital and Karolinska Institutet. Regulatory frameworks for experimental use are governed by agencies such as the Food and Drug Administration and the European Medicines Agency, while ethical review occurs through institutional review boards at institutions like Stanford University and University College London.

Patterns of Use and Epidemiology

Epidemiological surveillance by organizations such as the World Health Organization, United Nations Office on Drugs and Crime, and national public health agencies (for example, Centers for Disease Control and Prevention and Public Health England) tracks prevalence, initiation age, and demographic patterns. Use patterns vary regionally—high-consumption markets historically reported in United States, Spain, and United Kingdom; production concentrated in Andean states including Colombia, Peru, and Bolivia—and are described in datasets produced by research groups at University of California, Los Angeles and Imperial College London. Polydrug use patterns intersect with substances monitored by agencies like European Monitoring Centre for Drugs and Drug Addiction and are considered in public health responses in cities such as Miami, Barcelona, and London.

Health Effects and Toxicity

Acute effects include sympathomimetic stimulation, cardiovascular complications, and neurologic events; severe toxicity manifests as myocardial ischemia, stroke, and seizures, documented in case series from tertiary centers such as Mount Sinai Hospital and Royal Melbourne Hospital. Chronic use associates with nasal septum perforation, cardiomyopathy, neurocognitive deficits, and addiction syndromes investigated by researchers at National Institute on Drug Abuse, Scripps Research, and Yale School of Medicine. Overdose management protocols are discussed in emergency medicine guidelines from bodies including the American College of Emergency Physicians and European Resuscitation Council.

Production, Trafficking, and Legal Status

Cultivation, chemical processing, and trafficking routes link rural agricultural zones in Andean Community states with transshipment hubs in Central America and distribution networks reaching markets in North America, Europe, and Asia. Counter-narcotics operations have involved military and law-enforcement collaborations such as Plan Colombia and multinational task forces coordinated with agencies like the Drug Enforcement Administration and Interpol. International legal controls stem from treaties such as the Single Convention on Narcotic Drugs (1961) and decisions by the International Narcotics Control Board, while national scheduling regimes are enacted through legislatures in countries including United States Congress and UK Parliament.

Prevention, Treatment, and Harm Reduction

Prevention programs draw on public health strategies implemented by organizations like UNICEF and World Health Organization and local initiatives in school systems in municipalities such as New York City and São Paulo. Treatment modalities include psychosocial interventions developed in settings like Hazelden Betty Ford Foundation and medication-assisted approaches studied in trials at Columbia University and King's College London. Harm reduction measures—syringe services, overdose response training, and drug-checking pilots—have been piloted by NGOs and municipal programs in cities such as Vancouver, Lisbon, and Zurich, and evaluated by public health institutes including Robert Koch Institute and Instituto Nacional de Salud Pública.

Category:Stimulant drugs